This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Classical Phenylketonuria / PKU / Phenylalanine hydroxylase deficiency고전적 페닐케톤뇨증 (페닐케톤뇨증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.0 (Classical phenylketonuria) | OMIM: 261600 | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsPhenylketonuria (PKU), Phenylalanine hydroxylase deficiency, classical PKU, hyperphenylalaninemia type 1, Følling's disease
C. Adult onsetLikelihood of first onset in adulthood: very low — most cases are detected within a few days after birth by newborn screening, and if untreated, neurodevelopmental delay progresses from infancy; if treatment is discontinued in adulthood, cognitive decline and maternal PKU problems may occur.
1. History1934: Norwegian physician Ivar Asbjørn Følling first describes urinary excretion of phenylketones → 1950s: Bickel develops the low-phenylalanine diet → 1963: Guthrie newborn screening method introduced → 1983: PAH gene cloned → 2007: sapropterin (BH4) therapy approved.
2. CausesBiallelic pathogenic variants in the PAH gene located on chromosome 12 (12q23.2). PAH enzyme deficiency → inability to hydroxylate phenylalanine → accumulation of blood phenylalanine ≥1,200 μmol/L or more → production of neurotoxic metabolites (phenylpyruvic acid, phenylacetic acid, etc.).
3. GeneticsAutosomal recessive. More than 1,000 PAH gene variants reported (ClinVar). Main variants in Koreans: IVS4+5G>T, R408W, R243Q, etc. Compound heterozygosity is common. A genotype-phenotype correlation exists; residual enzyme activity determines phenotypic severity.
4. General epidemiologyWorldwide average birth frequency about 1:10,000–1:15,000. In Korea, about 1:70,000–1:80,000, lower than in Western countries. About 10–15 new cases are identified annually through domestic newborn screening. Equal occurrence in males and females. Incidence is high in some populations, such as Ireland and Turkey.
5. PathophysiologyPAH enzyme deficiency → excessive accumulation of blood phenylalanine → competitive inhibition of large neutral amino acid (LNAA) transport into the brain → reduced brain supply of tyrosine, tryptophan, and other LNAAs → decreased dopamine and serotonin synthesis → impaired myelination and abnormal neurotransmission → impaired cognitive development.
6. SymptomsIf untreated: from a few months of age, intellectual disability (IQ <50 in severe cases), seizures, behavioral abnormalities (hyperactivity, self-injury), eczematous skin rash, mousy odor (phenylacetic acid), light skin and hair color. With early treatment, normal development is possible in most cases. Untreated adults: anxiety, depression, cognitive decline.
7. SignsBlood phenylalanine ≥1,200 μmol/L (normal <120). Positive urine phenylketones (FeCl₃ reaction). White matter hyperintense lesions on brain MRI (if untreated or with poor dietary control). Developmental delay, microcephaly (in severe cases). Skin hypopigmentation, blue eyes, blond hair (reduced melanin synthesis).
8. ScreeningNewborn dried blood spot (Guthrie card) sampling at 48–72 hours after birth → measurement of blood phenylalanine and the Phe/Tyr ratio by tandem mass spectrometry (MS/MS). A mandatory item of the national newborn screening in Korea. If positive, quantitative plasma amino acid analysis and urine pterin testing to differentiate BH4 deficiency.
9. DiagnosisQuantitative plasma amino acid analysis (phenylalanine ≥1,200 μmol/L). Urine organic acid analysis (phenylketones). Measurement of erythrocyte DHPR activity (to differentiate BH4 deficiency). Urine pterin profile (biopterin, neopterin). Molecular genetic testing of the PAH gene (NGS panel or single gene). BH4 loading test (change in Phe over 24 hours after oral administration of sapropterin 20 mg/kg).
10. TreatmentLow-phenylalanine diet (restriction of natural protein + supplementation with phenylalanine-free amino acid formulas) — maintained for life. Sapropterin dihydrochloride (Kuvan®, BH4-responsive group about 25–50%): target reduction in blood Phe of 30% or more. Pegvaliase (Palynziq®, PEGylated PAL enzyme substitution): adults with severe PKU. Maintain blood Phe <360 μmol/L during pregnancy (maternal PKU management).
11. PrognosisNormal intelligence and development are possible if treatment is started within the first month of life and blood Phe is maintained within the target range (120–360 μmol/L). Risk of cognitive decline and white matter abnormalities with delayed treatment or poor dietary control. Maternal PKU: very high risk of fetal malformations (microcephaly, congenital heart malformations, growth retardation) if blood Phe is uncontrolled.
12. PreventionPrimary: genetic counseling, carrier and prenatal genetic testing. Secondary: national newborn screening (48–72 hours after birth), early start of dietary therapy (within the first month of life). Tertiary: regular monitoring of blood Phe, management of dietary adherence, follow-up of cognitive development; strict control of blood Phe starting before pregnancy in women with PKU planning pregnancy.
13. ReferencesBlau N et al. Phenylketonuria. Lancet. 2010;376(9750):1417-1427. and 9 other papers

1. History

The history of phenylketonuria (PKU) begins in 1934 with the groundbreaking clinical observation of the Norwegian physician Ivar Asbjørn Følling (1888–1973). Følling discovered a substance in the urine of two brothers with intellectual disability that turned green on reacting with ferric chloride (FeCl₃) reagent. He identified this substance as phenylpyruvic acid and proposed that this metabolic abnormality might be the cause of the intellectual disability. This achievement was the world's first case of intellectual disability with an identified biochemical cause and became the starting point of the field of inborn errors of metabolism. For some time, the disease was called "Følling's disease" or "phenylpyruvic oligophrenia".

In the 1950s, the British pediatrician Horst Bickel developed a special phenylalanine-restricted diet at Great Ormond Street Hospital in London. In 1953, Bickel's team applied a low-phenylalanine diet to a two-year-old child with PKU and reported marked improvement in clinical symptoms and intellectual function (PMID: 13075683). This discovery was the first case proving that an inborn metabolic disease can be treated with diet, changing the paradigm of treatment for metabolic diseases.

The most important milestone in the history of newborn screening is the Guthrie test, developed in 1963 by the American microbiologist Robert Guthrie. Using a bacterial inhibition assay, Guthrie developed a simple and inexpensive method for large-scale screening of PKU from dried blood spots (DBS) made from a small amount of blood taken from a newborn's heel. This method subsequently became the foundation of newborn screening systems worldwide and has enabled hundreds of thousands of children to avoid severe intellectual disability. In Korea, the Guthrie test began to be introduced in the 1970s, and PKU was subsequently included in the national newborn screening system.

In 1983, the phenylalanine hydroxylase (PAH) gene was cloned on the long arm of chromosome 12 (12q23.2), and hundreds of PAH variants were subsequently identified. In the 2000s, molecular genetic analysis was introduced into clinical practice, and studies of genotype-phenotype correlations became active. In 2007, sapropterin dihydrochloride (Kuvan®) was approved by the US FDA, providing the first drug treatment option for patients with BH4-responsive PKU. In 2018, pegvaliase (Palynziq®) was approved by the FDA as a treatment for adult PKU, offering a new treatment option for patients who respond insufficiently to dietary therapy.

In Korea, since 2006 the cost of newborn screening for 6 inborn metabolic diseases (including PKU) has been fully covered by the government, and expanded newborn screening using tandem mass spectrometry (MS/MS) is now carried out nationwide. PKU is classified as ICD-10 E70.0 and is assigned Special Copayment Reduction code V117, with a 10% copayment rate applied for 5 years after registration.


2. Causes

Classical phenylketonuria is an autosomal recessive metabolic disease caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene. The PAH gene is located on the long arm of chromosome 12 (12q23.2) and consists of 13 exons in total. This enzyme is expressed mainly in the liver and catalyzes the conversion of the essential amino acid phenylalanine (Phe) to tyrosine. This reaction requires tetrahydrobiopterin (BH4) as a cofactor, molecular oxygen, and iron ions.

When PAH enzyme activity is lost or markedly reduced, phenylalanine supplied through meals cannot be converted to tyrosine and accumulates excessively in the blood and tissues. The normal blood phenylalanine concentration is below 120 μmol/L, but in classical PKU it rises above 1,200 μmol/L without treatment. Excess phenylalanine is diverted into alternative metabolic pathways, producing abnormal metabolites such as phenylpyruvic acid, phenylacetic acid, and phenyllactic acid. These substances are excreted in the urine, causing a characteristic mousy odor, and have serious toxic effects on brain development.

More than 1,000 PAH gene variants worldwide are registered in ClinVar and PAHvdb, with missense variants being the most common (about 60%). Variants reported relatively often in Koreans include IVS4+5G>T (splicing variant), R408W (p.Arg408Trp), R243Q (p.Arg243Gln), and Y414C (p.Tyr414Cys). Most patients are compound heterozygotes carrying different variants on the two alleles, and homozygotes carrying two identical variants are relatively rare.

A genotype-phenotype correlation exists between the type of variant and residual PAH enzyme activity. Variants with 0–1% residual enzyme activity (e.g., R408W homozygosity) cause classical PKU, variants with 1–10% residual activity cause moderate PKU, and variants with 10% or more residual activity cause mild hyperphenylalaninemia (mild HPA). This classification has important implications for treatment strategy, especially for predicting response to BH4 (sapropterin). In general, the higher the residual enzyme activity, the more likely the response to BH4.

An important cause to be distinguished from PKU is tetrahydrobiopterin (BH4) deficiency. Because BH4 is an essential cofactor of PAH, defects in the BH4 synthesis or regeneration pathways (deficiencies of GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, dihydropteridine reductase, etc.) also cause hyperphenylalaninemia. These cases are classified as ICD-10 E70.1 (other hyperphenylalaninemias), and the treatment approach is fundamentally different. When hyperphenylalaninemia is identified on newborn screening, BH4 deficiency must be differentiated through urine pterin testing and measurement of DHPR enzyme activity.


3. Genetics

Phenylketonuria follows an autosomal recessive inheritance pattern. This means that the disease is expressed only when pathogenic variants are present on both alleles (inherited from both parents). Carriers (heterozygotes) with a variant on only one allele can live normally without clinical symptoms, and the carrier frequency in the population is estimated at about 1:50–1:100.

The causative gene, PAH (phenylalanine hydroxylase, OMIM *612349), is located on the long arm of chromosome 12 at q23.2, with a genomic size of about 79 kb and an mRNA length of 2.4 kb, and consists of 13 exons. The mature protein is a homotrimer made up of 452 amino acids, and each monomer consists of a regulatory domain, a catalytic domain, and a tetramerization domain. At the catalytic active center, non-heme iron is coordinated and participates in oxygen activation.

As of 2024, more than 1,000 pathogenic and likely pathogenic variants are registered in the worldwide PAH variant database (PAHvdb, locus-specific database). By variant type, missense variants are the most common at about 60%, followed by splicing variants about 13%, deletions/insertions about 13%, nonsense variants about 8%, and large rearrangements (exon deletion/duplication) about 3%. The main variants reported in Korean PKU patients are IVS4+5G>T, p.Arg408Trp (R408W), p.Arg243Gln (R243Q), p.Tyr414Cys (Y414C), and p.Val388Met (V388M), some of which are classified as East Asia-specific variants.

In terms of genotype-phenotype correlation, patients homozygous for p.Arg408Trp have residual enzyme activity close to 0%, show the severe phenotype of classical PKU, and do not respond to BH4. In contrast, variants such as p.Tyr414Cys and p.Ile306Val retain moderate activity and may show BH4 responsiveness. These genotype-phenotype correlations are used to establish personalized treatment plans.

In terms of genetic counseling, the recurrence risk for a child born to two carrier parents is 25% (1/4), with 50% being carriers and 25% having a normal genotype. Prenatal diagnosis is possible by molecular testing of the PAH gene using fetal DNA obtained by chorionic villus sampling (10–12 weeks of gestation) or amniocentesis (15–20 weeks of gestation). Preimplantation genetic testing (PGT) is also applicable. When the familial variant is already known, targeted variant analysis is recommended; when it is not known, sequencing of the entire PAH gene is recommended.


4. General epidemiology

Phenylketonuria is one of the most common inborn errors of amino acid metabolism worldwide and holds an important place among diseases targeted by newborn screening. The worldwide average birth frequency varies greatly by race and ethnicity but is generally reported as 1:10,000–1:15,000. By region, high incidence is observed in some Middle Eastern and European countries, such as Ireland (1:4,500), Turkey (1:5,000), and Iran (1:3,500). In contrast, it is relatively low in African and Asian populations.

In East Asia, including Korea, the incidence of PKU is markedly lower than in Western countries, reported as about 1:70,000–1:80,000 in Korea. According to the Health Insurance Review & Assessment Service (HIRA) and rare disease statistics in Korea, the number of registered patients is in the hundreds annually, and the number of newly diagnosed patients is around 10–15 per year. Japan similarly shows a low incidence of about 1:70,000–1:100,000. Among Han Chinese, it is reported at about 1:16,000, showing variation even within East Asia.

There is no difference in sex distribution between males and females (a feature of autosomal recessive inheritance), and the incidence increases with higher rates of consanguineous marriage within certain ethnic groups. Among inborn metabolic diseases, PKU has been included as a target of newborn screening in Korea for the longest period, and the rate of early detection has improved further since the introduction of tandem mass spectrometry.

Worldwide, PKU patients are classified according to blood phenylalanine concentration into classical PKU (Classical PKU, Phe >1,200 μmol/L when untreated), moderate PKU (Moderate PKU, Phe 900–1,200 μmol/L), mild PKU (Mild PKU, Phe 600–900 μmol/L), and mild hyperphenylalaninemia (Mild HPA, Phe 120–600 μmol/L). Classical PKU accounts for about 30–40% of all PAH deficiency, and the distribution varies by race according to genotype. There are also reports that the proportion of mild HPA is higher in Korean patients than in Western patients.

From a public health perspective, with the widespread adoption of newborn screening and early treatment, intellectual disability due to PKU has become almost entirely preventable in developed countries. However, lifelong adherence to dietary therapy and management of maternal PKU remain major public health challenges. Problems with discontinuation of or poor adherence to dietary therapy leading to neuropsychological complications in adult PKU patients also continue to be reported.


5. Pathophysiology

The key pathophysiological mechanism of nervous system damage in PKU is abnormal neurotransmitter metabolism and impaired myelination in the brain due to excessive accumulation of blood phenylalanine. When the PAH enzyme is deficient, phenylalanine ingested in the diet cannot be converted to tyrosine and accumulates in the blood. High concentrations of phenylalanine saturate the large neutral amino acid (LNAA) transporter (LAT1/SLC7A5) at the blood-brain barrier (BBB), competitively inhibiting the entry into the brain of other LNAAs (tyrosine, tryptophan, leucine, isoleucine, valine, histidine, threonine, the competing substrates of phenylalanine).

As a result, brain tyrosine concentrations decrease, reducing the synthesis of dopamine and norepinephrine. In addition, a lack of tryptophan reduces serotonin synthesis. Because dopamine and serotonin are essential for prefrontal cortical function, attention, and executive function, their deficiency causes cognitive impairment and behavioral abnormalities. Phenylalanine and its metabolites (phenylpyruvic acid, phenyllactic acid) also directly inhibit mitochondrial complexes I and III, causing abnormal energy metabolism.

Impaired myelination is also an important mechanism of PKU neuropathology. Tyrosine is required for the synthesis of myelin proteins, and phenylalanine excess and tyrosine deficiency impair myelin formation by oligodendrocytes. This is the pathological basis of the white matter hyperintense lesions (T2 hyperintensity in white matter) observed on brain MRI. It has been reported that these white matter changes can improve reversibly in PKU patients with poor blood Phe control.

During fetal life, maternal blood phenylalanine crosses the placenta to the fetus, and because the PAH enzyme is not yet sufficiently expressed in the fetus, maternal hyperphenylalaninemia directly damages fetal brain development. This is the mechanism of maternal PKU syndrome; unless blood Phe is maintained at or below 120–360 μmol/L from before pregnancy, the risks of fetal microcephaly, congenital heart malformations, growth retardation, and intellectual disability increase greatly.

The mechanism of response to BH4 (sapropterin) is understood to be that BH4 acts as a molecular chaperone that stabilizes the folding of the PAH protein and increases enzyme-substrate affinity. Therefore, in patients with mild to moderate PKU in whom residual PAH protein is present, BH4 supplementation increases the remaining enzyme activity and lowers blood Phe. In contrast, when almost no PAH protein is produced or it is completely nonfunctional, as in R408W homozygosity, no BH4 response occurs.


6. Symptoms

The clinical symptoms of classical PKU vary greatly depending on whether early diagnosis and treatment are provided. Before newborn screening became widespread, or when no treatment is given, the following characteristic clinical features appear.

Neurodevelopmental impairment: the most serious and prominent symptom. Infants appear normal at birth, but psychomotor developmental delay begins to appear after a few months of age. Without treatment, severe intellectual disability (IQ <50) develops in the majority. It is accompanied by delayed language development, hyperactivity, attention deficit, and self-injurious behavior, and some also show autism spectrum disorder-like behaviors.

Seizures: occur in about 25–50% of untreated PKU patients. Types vary, including slow-wave, clonic seizures, and infantile spasms, and EEG abnormalities are also commonly observed. When blood Phe is controlled, seizure frequency and EEG abnormalities improve.

Skin and pigmentary abnormalities: reduced tyrosine lowers melanin synthesis, leading to decreased pigmentation of the skin, hair, and iris. Light skin, blond hair, and blue eyes are usually characteristic (particularly in Asian patients, relative depigmentation is observed compared with their ethnic background), and eczematous skin rash is also common.

Characteristic odor: phenylacetic acid is excreted in the urine and sweat, producing a characteristic musty or mousy odor. This odor is a classic clinical clue to PKU, but because PKU is now detected early by newborn screening, the chance of encountering it in actual clinical practice has greatly decreased.

Abnormal muscle tone: muscle stiffness (hypertonicity), exaggerated tendon reflexes (hyperreflexia), and unusual postures (flexed arms, legs spread widely when sitting) are observed.

With early treatment, most symptoms can be prevented, and adult PKU patients who maintain blood Phe within the target range (120–360 μmol/L) can have normal intellectual ability, education, and employment. However, even in well-managed adult PKU patients, neuropsychological symptoms such as reduced executive function, decreased information processing speed, and depression and anxiety are reported at a higher frequency than in the general population.


7. Signs

The clinical signs of classical PKU are identified through newborn screening and regular blood Phe monitoring. The main signs objectively identified in patients before treatment or with poor treatment are as follows.

Elevated blood phenylalanine concentration: in classical PKU before treatment, blood Phe rises to 1,200 μmol/L or more (normal <120 μmol/L). When measured from newborn dried blood spots by tandem mass spectrometry (MS/MS), a value exceeding 2 mg/dL (about 120 μmol/L) is judged positive, and additional confirmatory testing is performed.

Positive urine phenylketones: the urine turns blue-green on the ferric chloride (FeCl₃) test, or a yellow precipitate forms on the 2,4-dinitrophenylhydrazine (DNPH) test. This indicates the presence of phenylpyruvic acid, a keto acid, in the urine.

White matter abnormalities on brain MRI: in PKU patients who are untreated or poorly treated, hyperintense lesions in the periventricular and subcortical white matter are observed on T2-weighted images. This reflects impaired myelination, and partial improvement is possible with better blood Phe control.

Developmental delay and microcephaly: in untreated patients, psychomotor developmental delay progresses, and microcephaly with a small head circumference may be observed. Microcephaly reflects impaired brain growth.

Hypopigmentation findings: relative depigmentation of the skin (compared with ethnic background), light-colored hair, blue or gray-blue irises. This reflects decreased melanin synthesis due to reduced tyrosine.

Electroencephalogram (EEG) abnormalities: in patients with seizures, spike-and-slow-wave complexes, hypsarrhythmia, and focal abnormal waves may be observed.

During the prenatal period in maternal PKU, cardiac malformations, fetal growth restriction, microcephaly, etc. may appear as signs on fetal echocardiography, so pregnant women with PKU need regular obstetric monitoring.


8. Screening

PKU is the most representative success story of newborn screening. In the Republic of Korea, multiple diseases including PKU are screened in all newborns nationwide through the Congenital Metabolic Disorder Screening, and since 2006 the government has fully covered the cost of testing.

Standard newborn screening (DBS/MS/MS): dried blood spots (DBS) are collected by heel-prick blood sampling from the newborn at 48–72 hours after birth. These are analyzed by tandem mass spectrometry (MS/MS) to measure the blood phenylalanine (Phe) concentration and the Phe/tyrosine (Tyr) ratio. If Phe >120 μmol/L or Phe/Tyr >2.0, the result is judged positive, leading to retesting and additional confirmatory testing. The MS/MS method has both higher sensitivity and higher specificity than the earlier Guthrie bacterial inhibition assay and has the advantage of being able to screen for about 50 metabolic diseases simultaneously.

Screening to differentiate BH4 deficiency: in newborns positive for PKU, BH4 deficiency must be differentiated. The urine pterin profile (measurement of biopterin and neopterin) and measurement of erythrocyte DHPR (dihydropteridine reductase) activity are used to screen for BH4 deficiency. This is essential because the treatment approach is fundamentally different.

Confirmatory testing: if screening is positive, blood Phe concentration is measured accurately by quantitative plasma amino acid analysis, and pathogenic variants are identified by molecular genetic testing of the PAH gene. The BH4 loading test (measurement of blood Phe at 4 and 24 hours after a single oral dose of sapropterin 20 mg/kg) is used to assess BH4 responsiveness and plan treatment.

Family screening and prenatal diagnosis: when a PKU patient is diagnosed, screening of siblings and carrier testing of family members are recommended. In subsequent pregnancies of couples who already have a child with PKU, fetal diagnosis is possible through prenatal genetic testing (chorionic villus sampling or amniocentesis).


9. Diagnosis

PKU is confirmed through several stages of confirmatory testing after a positive newborn screen. The key goals of the confirmation process are classifying the severity of PKU and differentiating BH4 deficiency.

Quantitative plasma amino acid analysis: plasma amino acid analysis using ion-exchange chromatography or MS/MS enables accurate quantitative measurement of blood Phe. Classical PKU is defined as Phe ≥1,200 μmol/L (1,000 μmol/L by some criteria). At the same time, tyrosine is decreased or at the lower limit of normal, and the Phe/Tyr ratio is markedly increased.

Urine pterin profile: urinary neopterin and biopterin concentrations are measured by high-performance liquid chromatography (HPLC) or MS/MS. In deficiencies of BH4 synthesis enzymes, a specific pterin pattern appears, distinguishing them from PKU (PAH deficiency). In GTPCH deficiency, both pterins are decreased, and in PTPS deficiency, a pattern of increased neopterin and decreased biopterin is characteristic.

Measurement of erythrocyte DHPR enzyme activity: because dihydropteridine reductase (DHPR) deficiency impairs the BH4 regeneration pathway, DHPR enzyme activity is measured in DBS or blood to differentiate this subtype.

Molecular genetic testing of the PAH gene: NGS (next-generation sequencing)-based panel testing or single-gene testing (sequencing + exon deletion/duplication analysis) of the PAH gene is performed. Molecular diagnosis is essential for predicting severity, predicting BH4 responsiveness, family counseling, and prenatal diagnosis.

BH4 loading test: a single oral dose of sapropterin dihydrochloride 20 mg/kg is given, and blood Phe is measured before and at 4, 8, and 24 hours after administration. If Phe decreases by 30% or more from baseline after 24 hours, the patient is judged BH4-responsive, which serves as the criterion for determining the indication for BH4 treatment.

Neurodevelopmental and neuropsychological evaluation: after diagnosis, regular neurodevelopmental evaluation (Bayley Scales of Infant Development, K-WISC-IV, etc.) and brain MRI are recommended. This is important for monitoring treatment effect and assessing long-term prognosis.


10. Treatment

The fundamental goal of PKU treatment is to maintain blood phenylalanine within the target range (ages 0–12: 120–360 μmol/L; age 13 and older and adults: 120–600 μmol/L; pregnant women: 120–360 μmol/L). Currently available treatments are as follows.

Low-phenylalanine diet: the cornerstone of PKU treatment, which must be started within the first month of life and maintained for life. Intake of natural protein is strictly restricted (special low-protein PKU foods are used, since most foods contain protein), and a phenylalanine-free amino acid formula (Phe-free amino acid formula) containing essential amino acids, vitamins, and minerals must be adequately supplemented. Tyrosine is treated as an essential amino acid in PKU patients and requires separate supplementation. Because deficiencies of vitamin B12, calcium, iron, selenium, zinc, and omega-3 fatty acids can develop on a low-protein diet, regular nutritional monitoring is essential.

Sapropterin dihydrochloride (Kuvan®): a synthetic form of tetrahydrobiopterin (BH4) that, when given orally, significantly lowers blood Phe in patients with BH4-responsive PKU. It is approved for adults and children aged 4 years and older, at a dose of 10–20 mg/kg/day. In the BH4-responsive group, using it together with dietary therapy can relax dietary restrictions. In Korea, too, this drug is covered by National Health Insurance.

Pegvaliase (Palynziq®): an enzyme substitution therapy in which phenylalanine ammonia lyase (PAL) derived from a bacterium (Anabaena variabilis) is conjugated with PEG. It is administered by subcutaneous injection and degrades blood Phe by bypassing the metabolic pathway. It is used in adult PKU patients who respond insufficiently to existing treatments. Major adverse effects include anaphylaxis, arthralgia, and injection site reactions, so observation for 60 minutes after administration is needed. It is currently not approved in Korea.

Maternal PKU management: pregnancy in women with PKU requires special care. Blood Phe must be maintained at or below 120–360 μmol/L from before pregnancy, and during pregnancy, blood Phe monitoring every 2–3 days and intensive management by a specialized metabolic dietitian are needed. If not properly controlled, the risk of maternal PKU syndrome (fetal microcephaly, cardiac malformations, growth retardation, intellectual disability) is very high.

Gene therapy (research stage): AAV-mediated liver-directed gene therapy is in the preclinical and early clinical trial stage. It supplies the enzyme by introducing a normal PAH gene into hepatocytes. It is anticipated as a long-term treatment option.


11. Prognosis

The prognosis of PKU is determined by the timing of treatment initiation and the quality of blood Phe control. Patients who start treatment within the first month of life after newborn screening and continuously maintain blood Phe within the target range can have normal intelligence (mean IQ 90–100 or higher), normal academic achievement, and social functioning.

However, even in well-controlled PKU patients, subtle deficits in executive function, processing speed, and attention compared with the general population are reported. This reflects chronic vulnerability of the dopamine pathways in the brain. In adult PKU patients, the frequency of depression, anxiety disorders, and ADHD symptoms is reported to be higher than in the general population.

Reduced adherence to dietary therapy commonly occurs in adolescence and adulthood. If blood Phe control becomes poor during this period, worsening of white matter abnormalities on brain MRI, cognitive decline, and mood disorders may occur. Reinforcing dietary therapy in adulthood may partially restore MRI findings and cognitive function, but complete recovery is not always guaranteed.

The success or failure of maternal PKU management is decisive for pregnancy outcomes. Women with PKU who achieve strict Phe control from before pregnancy can expect pregnancy outcomes nearly equivalent to those of other women. In contrast, if control fails, the risks of microcephaly, intellectual disability, and cardiac malformations in the child increase markedly.

Since the introduction of BH4 treatment or pegvaliase treatment, quality of life and blood Phe control have improved in some patients, and advances in gene therapy are expected to offer the possibility of a more fundamental cure in the future.


12. Prevention

Prevention of PKU is carried out comprehensively at the primary (preventing occurrence), secondary (early detection), and tertiary (preventing complications) levels.

Primary prevention: genetic counseling is recommended when there is a family history of PKU. Recurrence risk is determined by genetic testing of carrier parents, and affected fetuses can be detected early through prenatal genetic diagnosis (chorionic villus sampling or amniocentesis) or preimplantation genetic testing (PGT-M). Avoiding consanguineous marriage is also a general principle for preventing autosomal recessive diseases.

Secondary prevention (early detection): national newborn screening (DBS sampling at 48–72 hours after birth + MS/MS analysis) is key. When screening is positive, a rapid follow-up testing system aiming for confirmation and initiation of treatment within 2–4 weeks of birth is important. In Korea, this process is operated systematically through the Congenital Metabolic Disorder Screening and Patient Management Program.

Tertiary prevention (minimizing complications): after confirmation, long-term follow-up management is provided, including regular blood Phe monitoring (weekly initially, every 1–3 months once stable), dietary guidance led by a specialized metabolic dietitian, neurodevelopmental evaluation (at least once a year), and brain MRI (when necessary). For women with PKU planning pregnancy, intensive Phe control starting 6 months before pregnancy is emphasized. Psychological support and connection with patient networks are also important for maintaining quality of life.

From a public health perspective, important policy tasks are the continued expansion and quality control of newborn screening, strengthening of systems linking confirmed cases to treatment, and ensuring access to treatment through insurance coverage of special PKU foods and medicines.


13. References

  1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417-1427. DOI: 10.1016/S0140-6736(10)60961-0
  2. van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36. DOI: 10.1038/s41572-021-00267-0
  3. Levy HL, Sarkissian CN, Scriver CR. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria. Mol Genet Metab. 2018;124(4):223-229. DOI: 10.1016/j.ymgme.2018.06.002
  4. Keil S, Anjema K, van Spronsen FJ, et al. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics. 2013;131(6):e1881-e1888. DOI: 10.1542/peds.2012-3291
  5. Longo N, Dimmock D, Levy H, et al. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2019;21(8):1851-1867. DOI: 10.1038/s41436-019-0409-3
  6. Scala I, Concolino D, Della Casa R, et al. Long-term follow-up of patients with classical phenylketonuria after neonatal diagnosis: the southern Italy experience. J Inherit Metab Dis. 2012;35(6):1031-1038. DOI: 10.1007/s10545-012-9481-y
  7. Kim SW, Yoo HW, Kim GH, Lee BH. The Korean experience with expanded newborn screening and an update on the genotypic and phenotypic characteristics of Korean patients with phenylketonuria. J Hum Genet. 2014;59(5):309-314. DOI: 10.1038/jhg.2014.12
  8. Koch R, Moseley KD, Yano S, et al. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab. 2003;79(2):110-113. DOI: 10.1016/s1096-7192(03)00078-1
  9. Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-200. DOI: 10.1038/gim.2013.157
  10. Rohr F, van Calcar SC, Gleason ST, et al. Observations from a survey of states and countries on their newborn screening programs and follow-up for classical phenylketonuria. JIMD Rep. 2025;66(1):e12401. DOI: 10.1002/jmd2.12401